Lung cancer trials in Germany

In Germany 182 Also abroad 2744

182 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 12 November 2026. Ask the study team whether a trial fits you.

Phase 2Taking people
Repotrectinib in ROS1-positive Non-small Cell Lung Cancer Patients With Active Brain Metastasis
Where
Cologne, Hamburg, Hemer, Munich
Age
18 years and over
People
20 worldwide
Run by
MedSIR
See details and how to joinNCT06315010 · EU 2023-508112-35-00
Phase 3Taking people
Roll Over StudY for Patients Who Have Completed a Previous Oncology Study with Durvalumab
Where
Guetersloh, Muenster, Oldenburg
Age
18 years and over
People
87 worldwide
Run by
Astrazeneca AB
See details and how to joinNCT05303532 · EU 2023-507337-22-00
Phase 1/2Taking people
Study of FIH of STX-241 in Locally Advanced or Metastatic NSCLC Resistant to EGFR TKIs
Where
Berlin, Dresden, Munich
Age
18 years and over
People
171 worldwide
Run by
Pierre Fabre Medicament
See details and how to joinNCT06567015 · EU 2023-510203-21-00
Phase 3Taking people
Study of Sacituzumab Govitecan Versus Standard of Care in Participants with Previously Treated Extensive Stage Small Cell Lung Cancer
Where
Berlin, Bochum, Chemnitz, Esslingen am Neckar, Gera, Hamburg, Hemer, Loewenstein, Minden, Munich
Age
18 years and over
People
355 worldwide
Run by
Gilead Sciences Inc.
See details and how to join2024-515884-69-00
Phase 1/2Taking people
Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors
Where
Freiburg im Breisgau, Heidelberg, Ulm
Age
18 years to 100 years
People
280 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT06726148 · EU 2024-517281-42-00
No phaseTaking people
UmbREALung - A Retrospective and Prospective, Observational, Real World Multi-cohort Study of Patients With Non-small Cell Lung Cancer (NSCLC) Initiating Approved Drugs Developed by AZ or as Part of an AZ Alliance
Where
Berlin, Dresden, Frankfurt am Main, Halle, Hamburg, Hanover, Heidelberg, Kassel, Landshut, L Rrach, Magdeburg, M Nnerstadt, Neuss, Schorndorf, Wiesbaden
Age
18 years and over
People
300 worldwide
Run by
AstraZeneca
See details and how to joinNCT06726720
Phase 3Taking people
Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer
Where
Berlin, Cologne, Erfurt, Frankfurt am Main, Goettingen, Immenhausen, Kiel, Mainz, Munich
Age
18 years and over
People
582 worldwide
Run by
AstraZeneca
See details and how to joinNCT06350097 · EU 2023-509883-89-00
Phase 2Not yet taking people in Germany
A Trial for the Treatment of Advanced Large-Cell Neuroendocrine Cancer of the Lung
Where
Berlin, Dresden, Essen, Frankfurt Am Main, Gauting, Grosshansdorf, Heidelberg, Hemer, Mainz, Oldenburg, Stuttgart
Age
18 years and over
People
75
Run by
Technische Universität Dresden
See details and how to joinNCT07561645 · EU 2025-524345-28-00
No phaseTaking people
Social Prescriptions and Micro-Learning to Improve Care for Cancer Patients and Their Support Persons
Where
Augsburg, Bayreuth, Berlin, Cologne, Erlangen, Regensburg, Würzburg
Age
18 years and over
People
384
Run by
University of Regensburg
See details and how to joinNCT07788729
Phase 3Not yet taking people in Germany
Does a higher radiation dose prolong survival of patients with limited-stage small cell lung cancer receiving immunotherapy after chemotherapy and radiation therapy (DAHRTS trial)?
Where
Bochum, Bonn, Dresden, Essen, Frankfurt Am Main, Freiburg im Breisgau, Goettingen, Homburg, Kiel, Lemgo, Mainz, Regensburg, Rostock, Tuebingen
Age
18 years and over
People
426 worldwide
Run by
Norges Teknisk-Naturvitenskapelige Universitet NTNU
See details and how to join2026-525513-31-00
Phase 1Taking people
Study of Tarlatamab + ZL-1310 +/- Anti-programmed Death Ligand 1 (Anti-PD-L1) in Small Cell Lung Cancer (SCLC)
Where
Berlin, Dresden, Wuerzburg
Age
18 years to 99 years
People
160 worldwide
Run by
Amgen
See details and how to joinNCT07531095 · EU 2025-522888-15-00
Phase 2Taking people
Phase 2, Multicenter, Open label, Platform Study investigating Tarlatamab (AMG 757) in patients with Metastatic/Locally Advanced Small-Cell Lung Cancer (SCLC) and Other Poorly Differentiated Neuroendocrine Carcinomas (NECs), with biomarker analysis to characterize response/resistance (UNLOCK TARLATAMAB)
Where
Essen
Age
18 years and over
People
41 worldwide
Run by
Institut Gustave Roussy
See details and how to join2024-515847-47-00
Phase 1/2Taking people
A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
Where
Dresden, Essen, Frankfurt, Ulm, Würzburg
Age
18 years and over
People
1,109 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT04895709
Phase 2Not yet taking people in Germany
A trial to learn how safe newer immunotherapy drugs are and how well they work with or without other anti-cancer drugs in adults with advanced, unresectable non-small cell lung cancer
Where
Frankfurt Am Main, Freiburg im Breisgau, Homburg
Age
18 years and over
People
11 worldwide
Run by
AstraZeneca AB
See details and how to join2025-523599-21-00
Phase 3Taking people
Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide versus Durvalumab, Carboplatin, and Etoposide in First-Line ES-SCLC (DeLLphi-312)
Where
Chemnitz, Cologne, Dresden, Essen, Frankfurt am Main, Gauting, Grosshansdorf, Kiel, Luebeck, Wuerzburg
Age
18 years and over
People
156 worldwide
Run by
Amgen Inc.
See details and how to join2024-520050-38-00
Phase 3Taking people
A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer
Where
Berlin, Erfurt, Essen, Frankfurt am Main, Frankfurt Am Main, Gauting, Gera, Giessen, Goettingen, Hamburg, Immenhausen, Kiel, Minden, Oldenburg, Ulm
Age
18 years and over
People
540 worldwide
Run by
Daiichi Sankyo
See details and how to joinNCT06203210 · EU 2023-509628-16-00
Phase 1Taking people
AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors
Where
Essen
Age
18 years and over
People
434 worldwide
Run by
Amgen
See details and how to joinNCT07094113
Phase 1Taking people
Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
Where
Cologne, Essen, München, Rostock
Age
18 years to 100 years
People
162 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT06562192
Phase 2Taking people
DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers
Where
Berlin, Dresden, Erlangen, Gauting, Grosshansdorf, Heidelberg, Mainz
Age
18 years and over
People
204 worldwide
Run by
Boehringer Ingelheim
See details and how to joinNCT05882058 · EU 2023-504247-13-00
Phase 1Taking people
Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer
Where
Cologne, Frankfurt am Main, Hamburg, Mainz
Age
18 years and over
People
320 worldwide
Run by
BioNTech SE
See details and how to joinNCT05142189 · EU 2023-509283-14-00
Phase 1Taking people
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
Where
Berlin
Age
18 years and over
People
714 worldwide
Run by
Seagen, a wholly owned subsidiary of Pfizer
See details and how to joinNCT05208762 · EU 2023-506604-18-00
Phase 3Taking people
A Randomized, Double-Blind, Placebo-Controlled, MultiRegional Phase III Clinical Study of Toripalimab Alone or in Combination With Tifcemalimab (JS004/TAB004) as Consolidation Therapy in Patients With Limited-Stage Small Cell Lung Cancer Without Disease Progression Following Chemoradiotherapy
Where
Berlin
Age
18 years and over
People
147 worldwide
Run by
Shanghai Junshi Biosciences Co. Ltd.
See details and how to join2023-507097-41-01
Phase 2Taking people
Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer
Where
Berlin, Bonn, Dresden, Frankfurt Am Main, Hamburg, Mannheim, Munich
Age
18 years to 70 years
People
170 worldwide
Run by
Iovance Biotherapeutics, Inc.
See details and how to joinNCT04614103 · EU 2024-510778-26-00
Phase 1Taking people
Subcutaneous Tarlatamab in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-308)
Where
Regensburg, Wuerzburg
Age
18 years and over
People
220 worldwide
Run by
Amgen
See details and how to joinNCT06598306 · EU 2024-511838-12-00
Phase 2Not yet taking people in Germany
Phase II Study of Upfront SRT Plus Ivonescimab/Chemotherapy vs Ivonescimab/Chemotherapy in NSCLC Brain Mets
Where
Frankfurt Am Main, Jena, Rostock
Age
18 years and over
People
158 worldwide
Run by
European Organisation for Research and Treatment of Cancer - EORTC
See details and how to joinNCT07234877 · EU 2025-522985-60-00